PGPhilippe Godard

Philippe Godard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Philippe Godard has a total of 110 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 September 2006
      • Vol. 23, 10S5-10S6

    [Mediteranean environment and thoracic pathology].

    by P Godard, R Chiron, J-L Pujol, P Chanez, P Demoly, R Clavel, X Quantin, J Bousquet, C Prefaut

    • 1 June 2006
      • p. 8S9-8S55

    [A operational plan on behalf of chronic obstructive bronchopneumopathy. 2005-2010. Knowledge, prevention and improved management of COBP].

    by E Biron, P Carré, P Chanez, B Crestani, C Cretin, B Dautzenberg, B Eichler, P Godard, J-P Grignet, Y Grillet, et al.

  • Test à la méthacholine chez les athlètes olympiques

    by P. Kippelen, B. Housset, P. Rochcongar, F. Friemel, P. Godard


  • Open Access

    Implementing Practice Guidelines: A Workshop on Guidelines Dissemination and Implementation with a Focus on Asthma and COPD

    by Louis-Philippe Boulet, Allan Becker, Dennis Bowie, Paul Hernandez, Andrew McIvor, Michel Rouleau, Jean Bourbeau, Ian D Graham, Jo Logan, L&# Xe9, et al.

    The present supplement summarizes the proceedings of the symposium “Implementing practice guidelines: A workshop on guidelines dissemination and implementation with a focus on asthma and COPD”, which took place in Quebec City, Quebec, from April 14 to 16, 2005. This international symposium was a joint initiative of the Laval University Office of Continuing Medical Education (Bureau de la Formation Médicale Continue), the Canadian Thoracic Society and the Canadian Network for Asthma Care, and was supported by many other organizations and by industrial partners. The objectives of this meeting were to examine the optimal implementation of practice guidelines, review current initiatives for the implementation of asthma and chronic obstructive pulmonary disease (COPD) guidelines in Canada and in the rest of the world, and develop an optimal strategy for future guideline implementation. An impressive group of scientists, physicians and other health care providers, as well as policy makers and representatives of patients’ associations, the pharmaceutical industry, research and health networks, and communications specialists, conveyed their perspectives on how to achieve these goals.This important event provided a unique opportunity for all participants to discuss key issues in improving the care of patients with asthma and COPD. These two diseases are responsible for an enormous human and socioeconomic burden around the world. Many reports have indicated that current evidence‐based guidelines are underused by physicians and others, and that there are many barriers to an effective translation of recommendations into day‐to‐day care. There is therefore a need to develop more effective ways to communicate key information to both caregivers and patients, and to promote appropriate health behaviours. This symposium contributed to the initiation of what could become the “Canadian Asthma and COPD Campaign”, aimed at improving care and, hence, the quality of life of those suffering from these diseases.It is hoped that this event will be followed by other meetings that focus on how to improve the transfer of key recommendations from evidence‐based guidelines into current care, and how to stimulate research to accomplish this.


    • 1 April 2005
      • Vol. 22, 4S51-3

    [What is the role of the pneumologist in the management of asthma?].

    by P Godard, Y Grillet, R Clavel

    • 1 November 2003
      • Vol. 20, 701-9

    [Smoking habits, attitudes and knowledges of medical students of Medicine, Pharmacy and Odonto-Stomatology's Faculty of Dakar, Senegal].

    by M Ndiaye, M Ndir, X Quantin, P Demoly, P Godard, J Bousquet

    Smoking is a public health problem that does not spare the medical profession. We set out to determine the prevalence of smoking in medical students in Dakar and to assess their attitudes and knowledge in the face of this problem. A cross sectional study was conducted by means of an auto-questionnaire among 1547 medical students between 3 and 31 May 2001. There were 1061 males (68.6%) and 486 females (31.4%). The overall prevalence of regular or occasional smoking was 34.6%, with 42.8% in the first cycle, 38% in the second and 19% in the third. It was significantly higher among males at 76.4%. The average age of starting smoking ranged from 10 to 22 years and average duration from 5 to 26 years. The influence of fashion was the most frequent initiating factor at 37.4% and 96.6% smoked commercial cigarettes. Nicotine dependence, assessed by the Fagerstrom score, was average in 59.3%, strong in 14% and very strong in 4.7%. 58.8% smoked in public places and 78.2% thought they could give up smoking within the next 5 years. 8.4% were unaware of the effects of tobacco on health and 20.5% of the relationship between tobacco and the diseases quoted. 37.7% of future doctors would not systematically avoid smoking in the presence of patients but 79% wished to ban advertising and 70.4% to ban the use of tobacco in hospitals. 94.4% of students wanted health care workers to be educated about the effects of smoking. Tobacco smoking among medical students has increased between 1989 (28.7%) and 2001 (35.6%). This observation should stimulate the establishment of a course on the pathology of tobacco smoking and the integration of education and prevention within the medical curriculum, increase the awareness of smokers and above all help them stop.


    • 15 March 2001
      • Vol. 51  (5) , 533-7

    [Recommendations for the management of asthma].

    by J Bousquet, P Demoly, P Godard

    Recommendations for the management of asthma have been proposed for the last 15 years around the world. These recommendations have been internationalised and the latest one, the Global Initiative for Asthma (GINA) is a World Health Organisation--National Institutes of Health initiative. Asthma recommendations were initially based on opinion of experts but the newest will be evidence-based. The GINA guidelines concern diagnosis, assessment of severity and treatment of asthma. They include all parts of asthma treatment: allergen avoidance, immunotherapy, pharmacotherapy and education. These guidelines are applied in over 100 countries worldwide, and, in countries where they are applied, morbidity and mortality due to asthma have decreased.

    • 1 November 2000
      • Vol. 17  (5) , 925-30

    [From allergic rhinitis to sinus diseases (sinusitis/nasal polyps): epidemiologic and experimental links].

    by P Demoly, A M Bencherioua, L Crampette, H Dhivert-Donnadieu, P Godard, F B Michel

    The relationships between rhinitis and chronic sinusitis are close and complex, those between allergic rhinitis and nasal polyposis are controversial. These relationships can be demonstrated not only in terms of anatomy, physiology and epidemiology (by comparing the prevalence of one disease in patients suffering from the other disease), but also experimentally (by studying the sinus involvement following nasal allergen provocations), and pathophysiologically (by phenotyping and comparing the inflammation present in both diseases). Results of such studies are convincing and have confirmed the fundamental role of nasal inflammation in general and allergic inflammation in particular in the genesis of sinusitis (it is now therefore recommended to utilize the term 'rhinosinusitis'). The importance of allergy in the etiologic development of nasal polyps remains controversal and doubtful. Because the diagnosis of allergic rhinitis provides useful therapeutic options, an appropriate evaluation for underlying allergies in indicated in any patient with chronic upper respiratory tract symptoms.

    • 7 October 2000
      • Vol. 29  (29) , 1625-9

    [Asthma and rhinitis medications: pregnancy precautions].

    by P Demoly, D Jaffuel, P Godard, F B Michel, J Bousquet

    DRUG PRESCRIPTION: Many pregnant women have asthma and/or rhinitis. Particular attention is required when prescribing drugs in this situation. Medication can be prescribed during pregnancy when the apparent benefit is greater than the apparent risk. Usually at least one drug of each major class used to control these disease can be given safely. In addition, physiological changes associated with pregnancy could affect the upper and lower pathways. CAREFUL MANAGEMENT: Ideally, drug prescription for asthma and/or rhinitis in pregnant women should be part of a global process implicating obstetricians, primary care physicians, and allergy, rhinology or lung specialists. The only way to improve the mother's comfort and avoid complications for both mother and child is to perfectly control the disease. Indeed, it would be regrettable to be too prudent and deprive symptomatic patients of active treatments. Patients should be clearly informed of the benefits and risks of drug therapy.